Zymeworks Past Earnings Performance
Past criteria checks 0/6
Zymeworks has been growing earnings at an average annual rate of 18.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 54.3% per year.
Key information
18.4%
Earnings growth rate
21.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 54.3% |
Return on equity | -25.5% |
Net Margin | -156.1% |
Next Earnings Update | 02 May 2024 |
Recent past performance updates
Recent updates
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Zymeworks Inc. (NYSE:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 27We Think Zymeworks (NYSE:ZYME) Can Afford To Drive Business Growth
Nov 17Zymeworks: Drop Due To Low Differentiation Against Competition
Jul 05Zymeworks: Oncology Drug Discovery Company With Major Big Pharma Deals
Dec 11Zymeworks' zanidatamab nabs Breakthrough Therapy tag for biliary tract cancer
Nov 30Zymeworks' zanidatamab an Orphan Drug in Europe for gastric cancer
Nov 19Revenue & Expenses BreakdownBeta
How Zymeworks makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 76 | -119 | 70 | 0 |
30 Sep 23 | 462 | 205 | 87 | 0 |
30 Jun 23 | 448 | 186 | 86 | 0 |
31 Mar 23 | 446 | 173 | 80 | 0 |
31 Dec 22 | 412 | 124 | 75 | 0 |
30 Sep 22 | 30 | -224 | 49 | 0 |
30 Jun 22 | 32 | -237 | 49 | 0 |
31 Mar 22 | 28 | -240 | 53 | 0 |
31 Dec 21 | 27 | -212 | 42 | 0 |
30 Sep 21 | 22 | -211 | 50 | 0 |
30 Jun 21 | 21 | -223 | 56 | 0 |
31 Mar 21 | 31 | -194 | 49 | 0 |
31 Dec 20 | 39 | -181 | 55 | 0 |
30 Sep 20 | 25 | -215 | 72 | 0 |
30 Jun 20 | 30 | -173 | 63 | 0 |
31 Mar 20 | 26 | -163 | 62 | 0 |
31 Dec 19 | 30 | -145 | 63 | 0 |
30 Sep 19 | 57 | -64 | 40 | 0 |
30 Jun 19 | 51 | -52 | 36 | 0 |
31 Mar 19 | 65 | -29 | 31 | 0 |
31 Dec 18 | 53 | -37 | 30 | 0 |
30 Sep 18 | 74 | -13 | 28 | 0 |
30 Jun 18 | 72 | -11 | 26 | 0 |
31 Mar 18 | 52 | -16 | 19 | 0 |
31 Dec 17 | 52 | -11 | 18 | 0 |
30 Sep 17 | 4 | -55 | 19 | 0 |
30 Jun 17 | 6 | -51 | 16 | 0 |
31 Mar 17 | 11 | -47 | 17 | 0 |
31 Dec 16 | 11 | -34 | 13 | 0 |
30 Sep 16 | 10 | -30 | 9 | 0 |
31 Dec 15 | 10 | -19 | 5 | 0 |
31 Dec 14 | 2 | -13 | 4 | 0 |
Quality Earnings: ZYME is currently unprofitable.
Growing Profit Margin: ZYME is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ZYME is unprofitable, but has reduced losses over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: ZYME has a negative Return on Equity (-25.53%), as it is currently unprofitable.